Breaking News Instant updates and real-time market news.

GNBT

Generex

$3.78

0.04 (1.07%)

, MRK

Merck

09:31
07/31/17
07/31
09:31
07/31/17
09:31

Generex reports collaboration with Merck to evaluate Keytruda, AE37 combination

Generex Biotechnology (GNBT) announced that its wholly-owned subsidiary, Antigen Express, has entered into a clinical trial collaboration agreement with Merck (MRK), through a wholly-owned subsidiary, to evaluate Antigen's AE37 cancer vaccine in combination with Merck's anti-PD-1 therapy, KEYTRUDA, in patients with metastatic triple-negative breast cancer. The study will evaluate preliminary safety and efficacy of the combination in a Phase II trial. The combination of AE37 plus KEYTRUDA follows previous studies, in which both therapies have individually shown encouraging results in patients with triple-negative breast cancer. In a controlled, randomized trial of AE37 in 300 breast cancer patients, the most encouraging results were observed in those with triple-negative breast cancer. Similarly, KEYTRUDA has shown encouraging activity in patients with metastatic triple-negative breast cancer. The attractiveness of the combination lies in the different mechanisms of action of the two immunotherapeutic drugs: AE37 specifically activates T cells to attack cancer cells while KEYTRUDA increases the ability of the body's immune system to help detect and fight tumor cells. The collaboration agreement is between Antigen Express and Merck. Under the terms of the agreement, the trial will be sponsored by Antigen Express. Additional details were not disclosed.

GNBT

Generex

$3.78

0.04 (1.07%)

MRK

Merck

  • 28

    Aug

  • 22

    Sep

GNBT Generex
$3.78

0.04 (1.07%)

MRK Merck

07/27/17
GSCO
07/27/17
NO CHANGE
GSCO
Merck could trade up $5 following AstraZeneca MYSTIC failure, says Goldman Sachs
Goldman analyst Jami Rubin expects Merck (MRK) to trade up approximately $5 based on sentiment following AstraZeneca's MYSTIC failure as it partially de-risks longer-term estimates for Keytruda. As a result, the analyst raised Merck's Keytruda sales estimates by $600M in 2018 and $1B in 2019 and beyond, increasing earnings estimates by 14c-20c, and raising his price target on shares to $74 from $70. Rubin cautions that long-term estimates could be at risk if other competitor trials are successful. The analyst rates Merck a Neutral.
07/27/17
FBCO
07/27/17
NO CHANGE
FBCO
Merck unlikely to buy PARP company after Astra deal, says Credit Suisse
Credit Suisse analyst Alethia Young believes Merck (MRK) is unlikely to acquire a PARP inhibitor company like Tesaro (TSRO) or Clovis (CLVS) after inking an immuno-oncology deal with AstraZeneca (AZN).
07/27/17
JANY
07/27/17
NO CHANGE
Target $107
JANY
Buy
PARP deals may make Clovis more attractive buyout candidate, says Janney
The partnerships announced today between AstraZeneca (AZN) and Merck (MRK) as well as Tesaro (TSRO) and Takeda highlight pharma's willingness to expand on PARP's, Janney analyst Debjit Chattopadhyay tells investors in a research note. Clovis' (CLVS) Rubraca is now the only unencumbered PARP and is "far cheaper" on a relative valuation basis than peer Tesaro, the analyst adds. He believes Clovis could now become a more compelling takeover candidate. Chattopadhyay has a Buy rating on the shares with a $107 price target. The stock in midday trading is up 7%, or $5.90, to $93.33.
07/28/17
RHCO
07/28/17
NO CHANGE
RHCO
Merck, AstraZeneca deal positive, says SunTrust
After Merck (MRK) paid $1.6B upfront for access to Astrazeneca's (AZN) PARP inhibitor, Lynparza and another drug, SunTrust analyst John Boris says that the deal "makes strategic/financial sense and validates the PARP inhibitor class." He adds that the companies are "ideally positioned" to leverage a combination of IO and PARP therapies. The analyst reiterates a $73 price target and a Buy rating on Merck.

TODAY'S FREE FLY STORIES

SNSS

Sunesis

$2.87

0.01 (0.35%)

, ABBV

AbbVie

$93.60

-0.01 (-0.01%)

08:58
11/21/17
11/21
08:58
11/21/17
08:58
Initiation
Sunesis, AbbVie initiated  »

Oppenheimer says Sunesis…

SNSS

Sunesis

$2.87

0.01 (0.35%)

ABBV

AbbVie

$93.60

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$22.53

0.38 (1.72%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Technical Analysis
Technical View: DSW down sharply after earnings, outlook, miss consensus »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

A

Agilent

$69.96

1.17 (1.70%)

08:57
11/21/17
11/21
08:57
11/21/17
08:57
Recommendations
Agilent analyst commentary  »

Agilent price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

, BAC

Bank of America

$26.74

0.12 (0.45%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Options
Notable open interest changes for November 21st »

Monday's total…

GE

General Electric

$17.98

-0.23 (-1.26%)

BAC

Bank of America

$26.74

0.12 (0.45%)

BABA

Alibaba

$188.00

2.87 (1.55%)

AAPL

Apple

$169.98

-0.17 (-0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:55
11/21/17
11/21
08:55
11/21/17
08:55
Hot Stocks
Breaking Hot Stocks news story on Stone Energy »

Stone Energy trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NETS

Netshoes

08:53
11/21/17
11/21
08:53
11/21/17
08:53
Recommendations
Netshoes analyst commentary  »

Netshoes valuation overly…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$53.50

0.5 (0.94%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
Cubic analyst commentary  »

Cubic price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AXGN

AxoGen

$24.30

0.7 (2.97%)

08:51
11/21/17
11/21
08:51
11/21/17
08:51
Recommendations
AxoGen analyst commentary  »

AxoGen price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Campbell continues to expect Campbell Fresh to return to profitability this year »

Says back to normal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GE

General Electric

$17.98

-0.23 (-1.26%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Recommendations
General Electric analyst commentary  »

Deutsche Bank cuts target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:48
11/21/17
11/21
08:48
11/21/17
08:48
Hot Stocks
Eaton Vance reports AUM $382.4B for FY17 »

This represents an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

EV

Eaton Vance

$52.27

0.48 (0.93%)

08:46
11/21/17
11/21
08:46
11/21/17
08:46
Earnings
Eaton Vance reports Q4 adjusted EPS 70c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

MBI

MBIA

$8.95

-0.06 (-0.67%)

, GME

GameStop

$16.44

0.13 (0.80%)

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

MBI

MBIA

$8.95

-0.06 (-0.67%)

GME

GameStop

$16.44

0.13 (0.80%)

AAOI

Applied Optoelectronics

$43.48

-1.56 (-3.46%)

XLV

Health Care Select Sector SPDR

$80.90

-0.34 (-0.42%)

NUGT

Direxion Gold Miners Bull

$28.92

-0.88 (-2.95%)

OSTK

Overstock.com

$56.65

4.25 (8.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 28

    Nov

  • 29

    Nov

08:45
11/21/17
11/21
08:45
11/21/17
08:45
General news
U.S. October Chicago Fed National Activity index rose 0.29 points to 0.65 »

U.S. October Chicago Fed…

SSY

SunLink Health Systems

08:45
11/21/17
11/21
08:45
11/21/17
08:45
Hot Stocks
Breaking Hot Stocks news story on SunLink Health Systems »

Sunlink Health Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$81.46

1.24 (1.55%)

08:44
11/21/17
11/21
08:44
11/21/17
08:44
Recommendations
Lowe's analyst commentary  »

Lowe's quarter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

PANW

Palo Alto Networks

$142.53

-0.19 (-0.13%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Palo Alto Networks analyst commentary  »

Palo Alto Networks price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 11

    Dec

  • 17

    Jan

  • 17

    Jan

CPB

Campbell Soup

$49.93

0.21 (0.42%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Hot Stocks
Campbell Soup says expects to complete Pacific Foods acquisition by year-end »

Says saw lower seasonal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

SHOP

Shopify

$108.56

3.67 (3.50%)

, FB

Facebook

$178.74

-0.26 (-0.15%)

08:43
11/21/17
11/21
08:43
11/21/17
08:43
Recommendations
Shopify, Facebook analyst commentary  »

Shopify price target…

SHOP

Shopify

$108.56

3.67 (3.50%)

FB

Facebook

$178.74

-0.26 (-0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

, RAD

Rite Aid

$1.56

-0.03 (-1.89%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Recommendations
Amazon.com, Rite Aid analyst commentary  »

Amazon pharmacy…

AMZN

Amazon.com

$1,126.31

-3.57 (-0.32%)

RAD

Rite Aid

$1.56

-0.03 (-1.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:41
11/21/17
11/21
08:41
11/21/17
08:41
Hot Stocks
Stone Energy, Talos to become wholly-owned subsidiaries of new holding company »

Under the terms of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:40
11/21/17
11/21
08:40
11/21/17
08:40
General news
Breaking General news story  »

Week of 11/18 Redbook to…

VKTX

Viking Therapeutics

$2.77

-0.02 (-0.72%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Initiation
Viking Therapeutics initiated  »

Viking Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QD

Qudian

$20.08

-1.12 (-5.28%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Periodicals
Netease reports China stops approving new online micro lenders, Bloomberg says »

China's Internet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGY

Stone Energy

$35.49

1.15 (3.35%)

08:39
11/21/17
11/21
08:39
11/21/17
08:39
Hot Stocks
Stone Energy, Talos Energy combination to have ADP of about 47 Mboe »

The combination will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.